أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

amgrow pty ltd - bifenthrin - suspension concentrate - bifenthrin pyrethroid active 100.0 g/l - insecticide

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

amgrow pty ltd - bifenthrin - suspension concentrate - bifenthrin pyrethroid active 100.0 g/l - insecticide

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - fipronil - bait - fipronil nitrile active 0.6 g/l - insecticide

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

turf culture pty ltd - bifenthrin; n-methyl-2-pyrrolidone; liquid hydrocarbon - emulsifiable concentrate - bifenthrin pyrethroid active 100.0 g/l; n-methyl-2-pyrrolidone solvent other 50.0 g/l; liquid hydrocarbon solvent other 605.0 g/l - insecticide

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - botulinum toxin type a 100 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a - powder for injection - 100 units - active: botulinum toxin type a 100 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a excipient: albumin sucrose - xeomin is indicated in adults for the treatment of: · cervical dystonia · blepharospasm · spasticity of the upper limb · upper facial lines -glabellar frown lines -lateral periorbital lines (crow's feet) - horizontal forehead lines

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - botulinum toxin type a 50 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a - powder for injection - 50 units - active: botulinum toxin type a 50 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a excipient: albumin sucrose - xeomin is indicated in adults for the treatment of: · cervical dystonia · blepharospasm · spasticity of the upper limb · upper facial lines -glabellar frown lines -lateral periorbital lines (crow's feet) - horizontal forehead lines

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

merz australia pty ltd - incobotulinumtoxina, quantity: 100 u - injection, powder for - excipient ingredients: albumin; sucrose - xeomin is indicated in adults for the treatment of:,? cervical dystonia (spasmodic torticollis),? blepharospasm,? spasticity of the upper limb,? chronic sialorrhea due to neurological disorders,? upper facial lines,- glabellar frown lines,- lateral periorbital lines (crow?s feet),- horizontal forehead lines,xeomin is indicated in children and adolescents aged 2 years to 17 years for the symptomatic treatment of:,? chronic sialorrhea due to neurological/neurodevelopmental disorders,? spasticity of the lower and/or upper limbs

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

merz australia pty ltd - incobotulinumtoxina, quantity: 50 u - injection, powder for - excipient ingredients: albumin; sucrose - xeomin is indicated in adults for the treatment of:,? cervical dystonia (spasmodic torticollis),? blepharospasm,? spasticity of the upper limb,? chronic sialorrhea due to neurological disorders,? upper facial lines,- glabellar frown lines,- lateral periorbital lines (crow?s feet),- horizontal forehead lines,xeomin is indicated in children and adolescents aged 2 years to 17 years for the symptomatic treatment of:,? chronic sialorrhea due to neurological/neurodevelopmental disorders,? spasticity of the lower and/or upper limbs

كندا - الإنجليزية - Health Canada

stila styles, llc - titanium dioxide - powder - 4.5% - titanium dioxide 4.5% - sunscreen agents

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

rebel distributors corp - zaleplon (unii: s62u433rmh) (zaleplon - unii:s62u433rmh) - zaleplon 10 mg - zaleplon is indicated for the short-term treatment of insomnia. zaleplon has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies (see clinical trials   under clinical pharmacology ). it has not been shown to increase total sleep time or decrease the number of awakenings. the clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. the final formal assessments of sleep latency were performed at the end of treatment. hypersensitivity to zaleplon or any excipients in the formulation (see also precautions). zaleplon is classified as a schedule iv controlled substance by federal regulation. abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. physical dependence is a state of adaption that is manifested by a specific withdrawal syndrome that can be produced by abrupt ces